CJC-1295 with DAC: Published Research

Introduction

The published peer-reviewed literature on CJC-1295 with DAC spans preclinical pharmacology, human pharmacokinetic and pharmacodynamic studies, animal model research, serum proteomics, and anti-doping detection science. CJC-1295 with DAC distinguished itself within the GHRH analog class by achieving one of the longest documented half-lives in the category, and the human pharmacodynamic data published between 2006 and 2009 remain primary reference points for its GH/IGF-1 axis pharmacology. This article summarizes the findings reported in primary peer-reviewed sources.

Methodology Types in the Published Literature

The CJC-1295 with DAC research corpus draws on four principal methodology types.

In vitro receptor and biochemistry studies characterized the DAC conjugation chemistry and its effects on DPP-4 stability and receptor activity using cell lines and plasma incubation assays. These studies established that the maleimide-albumin conjugate retained GHRH receptor agonist activity and displayed markedly reduced proteolytic degradation relative to unconjugated hGRF(1-29) [1].

Rodent pharmacology models were used to evaluate GH axis responses, growth normalization, and pharmacokinetics. The GHRH knockout (GHRHKO) mouse — a model with ablated endogenous GHRH signaling and consequently dwarfed phenotype — was employed to assess whether sustained GHRH-R agonism via a long-acting analog could restore somatic growth [2].

Human pharmacokinetic/pharmacodynamic (PK/PD) studies in healthy adult volunteers provided the most directly translatable data on GH and IGF-1 axis responses, pharmacokinetics, and secretory pattern preservation [3, 4].

Serum proteomics approaches were applied to characterize downstream molecular changes associated with CJC-1295-mediated GH/IGF-1 axis activation in human subjects [5].

Analytical and anti-doping chemistry studies developed and validated detection methods for CJC-1295 and related GHRH analogs in equine and human biological matrices [6, 7, 8].

Summary of Published Studies

Preclinical Pharmacological Characterization (Bhatt et al., 2005)

Bhatt and colleagues first reported the identification and characterization of CJC-1295 as a long-lasting GHRH analog in a 2005 paper in Endocrinology [1]. The authors synthesized three maleimido-derivatized hGRF(1-29) analogs and assessed their stability against DPP-4 cleavage and their ability to activate the GHRH receptor on anterior pituitary cells in rats. CJC-1295 — the tetra-substituted form with an N-epsilon-3-maleimidopropionamide-lysine C-terminal modification — was identified as the lead compound. The albumin-conjugated form displayed enhanced stability against in vitro DPP-4 degradation. In rat studies, CJC-1295 produced a 4-fold increase in GH area under the curve over a two-hour period compared with unconjugated hGRF(1-29). The authors characterized CJC-1295 as a stable and active GHRH(1-29) analog with an extended plasma half-life attributable to albumin binding.

Findings from this animal model do not establish safety or efficacy in humans. SpartaLabs makes no claims about the use of this compound.

Human Pharmacokinetics and GH/IGF-1 Axis Responses (Teichman et al., 2006)

The most widely cited human study was reported by Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2006 [3]. The investigators administered single doses of CJC-1295 to healthy adult volunteers and characterized the resulting plasma GH and IGF-1 responses. The study reported dose-dependent increases in mean plasma GH concentrations sustained for six days or more, and mean plasma IGF-1 elevations sustained for nine to eleven days, after a single administration. The estimated half-life of CJC-1295 was reported as 5.8 to 8.1 days — substantially extended compared with native GHRH or short-acting synthetic analogs. The authors reported that CJC-1295 was well tolerated in the study cohort, characterizing this as the first published human evidence for prolonged, pharmacologically driven GH/IGF-1 axis activation from a single GHRH analog administration.

Pulsatile GH Secretory Pattern Under Sustained Stimulation (Ionescu and Frohman, 2006)

A related study by Ionescu and Frohman, also published in the Journal of Clinical Endocrinology and Metabolism in 2006, examined the GH secretory pattern during sustained CJC-1295 stimulation in healthy adults [4]. Frequent GH sampling was used to characterize secretory dynamics. The investigators reported that episodic, pulsatile GH secretion persisted throughout the period of CJC-1295 action, with observed increases in pulse amplitude and interpulse trough concentrations compared with baseline. The authors noted that this pattern differed qualitatively from the tonic, non-pulsatile GH exposure produced by exogenous GH administration — an observation with relevance to the mechanistic study of GH axis physiology. The mechanistic basis for retained pulsatility under continuous GHRH-R stimulation, discussed in the context of somatostatin counter-regulation, remains a scientifically active question.

Normalization of Growth in the GHRH Knockout Mouse (Laza-Knoerr et al., 2007)

A preclinical study by Laza-Knoerr and colleagues published in the American Journal of Physiology — Endocrinology and Metabolism in 2007 evaluated the pharmacodynamic sufficiency of once-daily CJC-1295 in the GHRHKO mouse model [2]. Three groups of GHRHKO mice received CJC-1295 at dosing intervals of 24, 48, and 72 hours, with untreated GHRHKO mice and heterozygous controls as comparators. Animals receiving once-daily CJC-1295 were reported to achieve normal body weight and body length, whereas placebo-treated GHRHKO mice exhibited the characteristic growth deficit phenotype. The authors characterized the extended pharmacodynamic duration of CJC-1295 as sufficient to normalize somatic growth in the knockout model — a more favorable result than had been observed with twice-daily injections of shorter-acting GHRH analogs in the same model.

These animal model findings do not establish safety or efficacy in humans. SpartaLabs makes no claims about the use of this compound.

Serum Proteomics Following GH/IGF-1 Axis Activation (Sackmann-Sala et al., 2009)

Sackmann-Sala and colleagues applied two-dimensional gel electrophoresis and mass spectrometry to sera from healthy adult men before and approximately one week after CJC-1295 administration [5]. The investigation identified five protein species with statistically significant intensity changes: a decrease in apolipoprotein A1 and transthyretin isoforms, and increases in beta-hemoglobin, a C-terminal albumin fragment, and a combined immunoglobulin/albumin fragment. A linear correlation was reported between IGF-1 concentrations and one of the increased protein clusters. The authors interpreted these findings as evidence of downstream molecular consequences of CJC-1295-mediated GH/IGF-1 axis activation and proposed that the identified proteins could serve as potential biomarkers of GH and IGF-1 biological activity.

Anti-Doping Detection Research

Following its prohibition by WADA under Section S2 of the Prohibited List, CJC-1295 has been the subject of forensic and anti-doping analytical research — an active area that has produced peer-reviewed detection methodology applicable to multiple species.

Thevis and colleagues (2011) reported the identification of CJC-1295 in an unknown pharmaceutical preparation submitted by Norwegian police and customs authorities, using liquid chromatography-high resolution tandem mass spectrometry (LC-HRMS/MS) [6]. The authors confirmed a 29-amino acid peptide consistent with CJC-1295, demonstrating that forensic identification of the compound in seized materials was analytically feasible.

Hedman and colleagues (2018) developed an immuno-polymerase chain reaction (iPCR) screening method for CJC-1295 and related GHRH analogs in equine plasma [7]. The method achieved detection sensitivity sufficient for anti-doping applications and was designed to accommodate the conjugated and unconjugated forms of the analyte.

A subsequent study by the same group (2019) reported a confirmatory LC-MS/MS method for CJC-1295 in equine plasma following immunoaffinity enrichment, achieving detection down to approximately 180 pg/mL [8]. The paper highlighted the analytical challenges posed by the large, heterogeneous albumin conjugate and advanced approaches to resolving them.

Active Research Frontier

The published CJC-1295 with DAC literature reflects a compound with a well-characterized preclinical and early-human pharmacological profile, with several questions remaining for further investigation. Comparative pharmacological data directly contrasting CJC-1295 with DAC to ghrelin-receptor agonists such as GHRP-6 — a structurally unrelated GH secretagogue that stimulates pituitary GH release through the GHS-R1a pathway — have not been published in head-to-head experimental designs.

Dose-response relationships, pharmacodynamics across age groups, and the effects of altered albumin concentrations or renal and hepatic function on pharmacokinetics were not the subject of the published human studies, which used healthy adult volunteer cohorts. These are recognized areas for prospective characterization. Long-term pharmacological effects of repeated CJC-1295 with DAC administration on pituitary somatotroph biology — including receptor desensitization and GH axis feedback dynamics — represent further frontiers for future research.

Comparative pharmacological data directly contrasting CJC-1295 with DAC to other GHRH analogs in head-to-head experimental designs have not been published, a gap that future preclinical or translational research could address. Researchers seeking batch-verified material can review analytical documentation for CJC-1295 with DAC on the SpartaLabs product page.

References

1. Bhatt DL, Bhatt S, Gagnon C, Castaigne JP, Frohman LA. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(9):3810-3818. PMID: 15817669. DOI: 10.1210/en.2004-1611.

2. Laza-Knoerr AL, Bhatt DL, Bhatt S, Frohman LA. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2007;292(4):E1062-E1069. PMID: 16822960. DOI: 10.1152/ajpendo.00201.2006.

3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683. DOI: 10.1210/jc.2005-1536.

4. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 16968793. DOI: 10.1210/jc.2006-1702.

5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19386527. PMC: PMC2787983. DOI: 10.1016/j.ghir.2009.03.001.

6. Thevis M, Kohler M, Thomas A, Walpurgis K, Schänzer W, Halter S, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2011;3(1):56-61. PMID: 21204297. DOI: 10.1002/dta.242.

7. Hedman E, Hansson A, Lantz I, Ljung A, Nyman M, Vessman J, et al. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. 2018;10(11-12):1789-1795. PMID: 30489688. DOI: 10.1002/dta.2529.

8. Hedman E, Hansson A, Lantz I, Ljung A, Nyman M, Vessman J, et al. A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Test Anal. 2019;11(6):886-893. PMID: 30938069. DOI: 10.1002/dta.2576.